

CURRICULUM VITAE



PERSONAL INFORMATION

Address **MEATTINI ICRO**
VIA DEL PONTORMO 70, 50141 – FLORENCE, ITALY
Phone n. **+39 339 3012019**
Fax **+39 055 7947363**
E-mail [**icro.meattini@unifi.it**](mailto:icro.meattini@unifi.it)
Nationality **Italian**
Date of Birth **AUGUST 11, 1980**

WORK EXPERIENCE

2024 – present

Head, Breast Unit, Azienda Ospedaliero-Universitaria Careggi (AOUC), Florence University Hospital, Florence, Italy

Chair, Breast Cancer Multi-Disciplinary Team (MDT), AOUC, Florence University Hospital, Florence, Italy

2018 – present

Associate Professor, Radiation Oncology, Department of Experimental and Clinical Biomedical Sciences “M. Serio”, University of Florence, Florence, Italy

Consultant, Radiation and Clinical Oncologist, Radiation Oncology Unit, AOUC, Florence University Hospital, Florence, Italy

Chair, Breast Cancer MDT for Radiation Oncology (2012 – present)

Head, Clinical Research Unit, Radiation Oncology Department (2017 – present)

2018 – 2029

National Scientific Qualification I level, Full Professor for Radiation Oncology (Scientific Disciplinary Sector [SSD] MED/36)

2011 – 2018

Consultant, Radiation/Clinical Oncologist

AOUC Florence University Hospital, Florence, Italy

Radiation Oncology Unit, Oncology Department

2010 – 2011

Research Fellow on “Evaluation of genetic predisposition to induced radio toxicity” at Radiation Oncology Unit, Oncology Department, AOUC Florence University Hospital, University of Florence, Florence, Italy

EDUCATION AND TRAINING

2017 – 2019

European Organisation for Research and Treatment of Cancer (EORTC)

Early Career Investigators (ECI) Leadership Program for the management of Clinical Research in Oncology

2016 – 2018

University of Brescia, Brescia, Italy

II Degree Master on “Oncologic Drugs and Radiotherapy”. Dissertation thesis “Hypofractionation in young breast cancer patients”. Supervisor: Prof. Stefano M. Magrini

2005 – 2009

University of Florence, Florence, Italy

Postgraduate Degree in Radiation Oncology. Dissertation topic “Breast cancer in patients treated for Hodgkin lymphoma: University of Florence experience”. Supervisor: Prof. Giampaolo Biti. 70/70 cum Laude

2008 – 2009

Royal Marsden Hospital, London, UK

Fellowship at Royal Marsden Hospital, London (UK). Supervisor: Prof. Michael Brada.

2005 – 2006

University of Florence, Florence, Italy

Research fellow at Department of Clinical Physiopathology

Topic: "Risk-assessment in Radiotherapy". [European project LSHC-CT-2004-503564 of 6th program MAESTRO (Advanced Methods and Equipment for Simulation and Treatment in Oncology Radiology)].

1999 – 2005

University of Florence, Florence, Italy
Medical Degree. Dissertation topic "Localized prostate cancer treated with intensity-modulated radiation therapy (IMRT)" Supervisor: Prof. Giampaolo Biti. 110/110 cum Laude.

1994 – 1999

High School "N. Rodolico", Florence, Italy
Scientific High school degree. 100/100.

PERSONAL SKILLS

MOTHER TONGUE

ITALIAN

FOREIGN LANGUAGES

ENGLISH

UNDERSTANDING

Reading

C1

Listening

C1

SPEAKING

Spoken interaction

C1

Spoken production

C1

WRITING

C1

SPANISH

UNDERSTANDING

Reading

B2

Listening

B2

SPEAKING

Spoken interaction

B2

Spoken production

B2

WRITING

B2

Author of more than 300 peer-reviewed scientific publications in international journals,

available at: <https://www.ncbi.nlm.nih.gov/pubmed/?term=meattini+i>

h-index: 38 (Jul 13, 2025)

316 documents, 7075 citations by 5851 documents,

available at: <https://www.scopus.com/authid/detail.uri?authorId=23027824500>

Scopus ID: 23027824500

ORCID profile: 0000-0002-1861-2895

Organization and participation as a speaker at national and international scientific conferences.

- Local Organizing Committee of the XVII National Congress of the Italian Association of Radiotherapy Oncology (AIRO) 2007, Florence, Italy.
- Invited speaker. XXII AIRO National Congress. Rome. Topic: "Radiotherapy after neoadjuvant system therapy: irradiation of the lymph node chains? cons ". 17-20/11/2012.
- Invited speaker. Workshop topic: "Advanced Breast Cancer: Evidence and Future Perspectives". Montecatini Terme, Italy. 24/05/2013.
- Invited speaker. 17th ECCO - 38th ESMO - 32nd ESTRO. European Cancer Congress: Reinforcing Multidisciplinary. Amsterdam, Netherlands.
- Invited speaker in the Roundtable Session on "How to Improve Career Opportunities for Young Oncologists Across Europe". 27/09/2013-01/10/2013.
- Invited speaker. XXIII AIRO National Congress. Taormina, Italy. "Toxicity in associations with systemic therapies". 26-29/10/2013.
- Report. ESTRO 33, Vienna, Austria. Selected oral communication in the session Clinical. Topic: "Breast cancer. Toxicity of APBI using IMRT versus whole breast irradiation: 3-year follow-up of a Phase III randomized trial with first (presenting author) I. Meattini. 4-8 / 04/2014.
- Invited speaker. Workshop topic: "Aggressive disease and indolent disease in advanced stage breast cancer". Pontedera, Italy. 06/19/2014.
- Invited speaker. Workshop topic: "Metastatic breast cancer therapy: role of anthracyclines", Pisa, Italy. 08/10/2014.
- Invited speaker. Workshop topic: "Building the best therapeutic program for the BC+ HR+/HER2- patient", Montecatini, Italy. 31/10/2014.
- Invited speaker. XXIV AIRO National Congress. Padua, Italy. "Wide Angle in Oncological Radiotherapy 2014". 9-11/11/2014.
- Invited speaker. Topic: "Consensus on the new indication in the eribulin as second line therapy ", Reggio Emilia. 03/03/2015.
- Report. 3rd ESTRO Forum, Barcelona, Spain. Presentation as a poster discussion in the Clinical session. APBI versus whole breast irradiation in women age 70 years or older: a subgroup analysis of a phase 3 randomized trial with first (presenting author) I. Meattini. 24-28 / 04/2015.
- Consensus Conference speaker. Topic: from the practice of "follow up" to the culture of "survivorship care", organized by the Italian Association of Medical Oncology (AIOM). Rome, 10-11/09/2015.
- Invited speaker. XXV AIRO National Congress. Rimini, Italy. Symposium "Breast reconstruction and radiotherapy implications". 7-10/11/2015.
- Invited speaker. V AIRO ZOOM Journal Club 2015, Bologna, Italy. 19/02/2016.
- Invited speaker. Workshop Topic: "HER2 determination" amplification methods. AOUC Florence, Italy. 26/02/2016.
- Invited speaker. Workshop topic: "The Breast Unit as a model of care for gender medicine in the AOU Careggi", AOUC Florence, Italy. 08/03/2016.
- Invited speaker. "HER2 positive breast carcinoma: Highlights and perspectives". AOU Careggi Florence, Italy. 13/04/2016.
- Invited speaker. "We Breast". Workshop topic: "Treatment of HR +/HER2 metastatic breast cancer in postmenopausal patients: from literature to clinical practice. Chemotherapy and hormone therapy". Prato, Italy 14/06/2016.
- Invited speaker. Advisory Board. Topic: "Treatment of patients with ER + HER2 metastatic breast cancer with Everolimus plus Exemestane: sharing of clinical and practical aspects to optimize treatment and management of patients". Antignano (Livorno), Italy. 27/06/2016.

- Invited speaker. Sustainability forum and opportunities in the health sector. Roundtable "The new frontiers in oncology". Stazione Leopolda, Florence, Italy. 23/09/2016.
- Invited speaker. Workshop Topic: "The Government of Pharmaceutical Innovation: Models of Sustainable Management of Innovative and High Cost Oncology Drugs". Istituto Toscano Tumori, Florence, Italy. 27/09/2016.
- Scientific Commission of the XXVII and XXVIII National Congress of the Italian Association of Radiotherapy Oncology (AIRO). Rimini, Italy 2017-2018.
- Invited speaker. XXVI AIRO National Congress. Symposium: "Innovative drugs in breast cancer". Rimini, Italy. 30/09/2016 - 02/10/2016.
- Invited speaker. Conference "Primary therapy in breast cancer". Oncological Tuesdays of AIOM Toscana. Pisa, Italy. 04/10/2016.
- Invited speaker. Senological diagnostics seminary with interactive presentation. Topic: "Disease recovery: diagnosis and biological meaning. Utilities and limits of follow-up". Florence, Italy. 17-20/10/2016.
- Invited speaker. Itinerary section AIRO "Consensus for the irradiation of the mammary lymph node stations", Ospedale dell'Angelo di Venezia Mestre, Italy. 21/10/2016.
- Invited speaker. Brescia Meetings in Radiation Oncology. "International Research projects in cardio-oncology: focus on breast cancer". Brescia, Italy. 17-18 /11/2016.
- Report. ECCO 2017. Amsterdam, Netherlands. Proffered Paper Session: "Breast Cancer". Oral Presentation in a Proffered Paper Session. IMRT-Florence phase 3 trial: "Health-related quality of life analysis from the accelerated partial breast irradiation". 29/01/2017.
- Invited speaker. "Advanced Breast Cancer HR +: HER2- versus HER2 +. Open questions. BreastIng Work: aBC HR + / HER2 - an evolving panorama". Camogli, Italy 31/03/2017 - 01/04/2017.
- Invited speaker. Topic: "Lecture on External beam partial irradiation". ESTRO 36, Vienna, Austria. 5-9 /05/2017.
- Invited speaker. Topic: "Management of the patient with metastatic breast cancer". Pisa, Italy 11 May 2017.
- Consensus conference. Topic: "In situ carcinoma of the breast". Catania, Italy. 18-20/05/2017.
- Invited speaker. Topic: "Update Course in Cardio-Oncology". Pietrasanta, Italy. 15/09/2017.
- Invited speaker. Topic: "Metastatic breast carcinoma with positive hormone receptors. Which clinical entity?". Bergamo, Italy. 22-23/09/2017.
- Invited speaker. European Society for Radiation Oncology (ESTRO) and European Organization for the Research and Treatment of Cancer (EORTC). Speaker at the Annual Meeting of the Korean Society for Radiation Oncology (KOSRO). Seoul, Korea. 13/10/2017.
- Executive Committee of the IX edition of the Congress in Senology (AIS). Florence, Italy. 8-10/11/2017.
- Invited speaker. Topic: "Highlights in Radiotherapy. What news from the 2017 International Congresses"? "Il Cardello" Radiological Research Center. Rome, Italy. 25/01/2018.
- Executive Committee and Expert Board of the "2nd Think Tank meeting on research challenges in breast cancer", endorsed by ESTRO Assisi, Italy 1-3/03/2018.
- Local Organizer of the Spring Meeting of the Oncology Radiotherapy Group (ROG) of the European Organization for Cancer Research and Treatment (EORTC). Florence, Italy 11-13/03/2018.
- Invited speaker. Panel of Experts. 11th European Breast Cancer Conference (EBCC). Multidisciplinary Team in the Real-World session on "Young HER2 Negative Patients with Breast Cancer". Barcelona (Spain). 21-23/03/2018.
- ESTRO Conference 37, selected Oral Communication on: "DCIS treated with breast conservative surgery and radiotherapy: a national multicentre experience". Barcelona (Spain). 20-24/04/2018.
- Invited speaker. meeting "I se ed i ma del trattamento del carcinoma mammario metastatico ER+/HER2-". Ferrara, 11-12 May 2018.
- Invited Speaker. Brescia Meetings in Radiation Oncology "Immunity, drugs, radiation: from biology to contemporary clinical oncology". Brescia, 20-21 September 2018.
- Advisory Board coordinator. Corso ECM "Help Desk in aBC. Share the clinical experience". Firenze, 5 October 2018.
- Advisory Board. Breast Cancer Expert Meeting. Pisa, 13 November 2018.

- Invited Speaker. Annual Meeting Swedish Breast Medical Oncologist, Brostnologisk Forening (BOF). Hesselby Slott, Vallingby, Stockholm (Sweden). 23-25 January 2019.
- Panel of Experts. Breast Surgery Toolbox – Hirslanden Klinik St. Anna Brustzentrum (ESTRO representative). “A consensus and toolbox to improve breast conservation rates and to guide axillary management after preoperative systemic therapy (PST)”. Luzern (Switzerland). 8 February 2019.
- Invited Speaker. Meeting “Focus sulla chirurgia oncologica e ricostruttiva della mammella”. Pisa, 11-12 April 2019.
- Invited Speaker. ESTRO 38 Annual Meeting. SP-0463 Towards less radiotherapy in breast cancer treatment. Milan, 27-30 April 2019.
- Executive Committee and Invited Speaker. XI Edition Biannual Meeting “Attualità in Senologia (AIS)”. Firenze, 6-8 November 2019.
- Invited Speaker. VIII Breast Surgery Workshop. “Ductal carcinoma in situ of the breast”. Aarhus, 21-23 May 2019.
- Panel of Experts. III Skagen meeting. Skagen, 4-6 June 2019.
- Advisory Board. “HR+ 2020, Il carcinoma mammario avanzato in alta risoluzione”. Firenze, 21 June 2019.
- Invited Speaker. 29th Residential Course “Modern Radiotherapy, time issues and new drugs”. Roma, 21-23 October 2019.
- Invited Speaker. XXI Congress of the Brazilian Society of Radiotherapy. Rio de Janeiro (Brasil), 23-27 October 2019.
- Invited Speaker. ESMO Breast Cancer Virtual Meeting. “Is cardiac damage still relevant? And how can be avoided?”. Virtual, 23-24 May 2020.
- Invited Speaker. Biannual Meeting 12th European Breast Cancer Conference (EBCC-12) (virtual). European Society for Radiotherapy & Oncology (ESTRO) - State of the Art in Radiation Oncology 2020. The best treatment in breast cancer radiotherapy 3D vs. IMRT. Virtual, 2-3 October 2020.
- Invited Speaker. Breast Turkish International Meeting Breastambul (hybrid/virtual). Istanbul, virtual, 17-18 October 2020.
- Invited Speaker. ESTRO40 Annual Meeting (virtual). 28 Nov – 1 Dec 2020.
- Invited Speaker. World Congress of Brachytherapy 2020 (virtual). Debate: Partial Breast Irradiation with 1-3 fractions. Virtual, 6-8 May 2021.
- Invited Speaker. Highlights St. Gallen Breast Cancer Conference 2021. Webinar, 28 May 2021.
- Invited Speaker. MORE TIME MORE LIFE. “Advanced Breast Cancer HR+ HER2-, dagli studi alla pratica clinica: gli inibitori CDK4/6 sono davvero tutti uguali?”. Webinar, 2 July 2021.
- Invited Speaker. Senoforum Accademia di Senologia Umberto Veronesi. 15-16 July 2021.
- Invited Speaker. ESTRO41 Annual Meeting. Session: New endpoints for early breast cancer - Less is more? Presentation title: Health-related quality of life - Primary or surrogate endpoint? Madrid, 27-31 August 2021.
- Faculty member and Speaker. ESMO Virtual Preceptorship on Cancer Care in Elderly Patients. Radiotherapy in older patients. 2-3 September 2021.
- Faculty. Focus Group CNAO: Patologie mammarie. Webinar, 21 September 2021.
- Invited Speaker. Webinar ECM FAD “Il meraviglioso mondo dei PARP inibitori: dalla biologia molecolare alla pratica clinica”. Webinar, 23 September 2021.
- Faculty member and Invited Speaker. Breastics24h Breast Oncoplastic. Oncoplastic Multidisciplinary Board Meeting. Webinar, 25 September 2021.
- Invited Speaker and Faculty. ESSO Advanced Course on Breast Cancer Surgery. Live Virtual Course, 24 November 2021.
- Panel of Experts. Assisi ATTM. Assisi, 21-23 February 2022.
- Invited Speaker and Faculty. ESTRO APBI multidisciplinary Course. Virtual, 28-30 March 2022.
- Invited Speaker and Session Chair. Omission of radiation therapy. GBCC Annual Meeting. Seoul, Korea, April 2022.
- Invited Speaker, Chair, and selected proffered paper. ESTRO42 Annual Meeting. Copenhagen, 6-10 May 2022.
- Faculty and Invited Speaker. 2° Congresso Rete Senologica Toscana. Cortona, 13-14 May 2022.
- Invited Speaker and Faculty. ESMO Preceptorship programme on breast cancer. Live Virtual Course, 14-15 June 2022.

- Panel of Experts. IV Skagen meeting. Skagen, 21-23 June 2022.
- Faculty and Invited Speaker. 13th European Breast Cancer Conference (EBCC). Barcelona, Spain, 16-18 November 2022.
- Faculty and Invited Speaker. 18th St. Gallen International Breast Cancer Conference (SGBCC). Vienna, Austria, 15-18 March 2023.
- Invited Speaker. ESTRO 2023 Clinical Pre-meeting palliative care course. Vienna, Austria, 12 May 2023.
- Invited Speaker. ESTRO 2023 Annual Meeting. Vienna, Austria, 12-16 May 2022.
- Faculty. ESSO Advanced Course on Breast Cancer Surgery. Madrid (SP), 28-30 September 2023.
- Invited Speaker. 42nd Congress of the European Society of Surgical Oncology. Florence, Italy, 25-27 October 2023.
- Faculty. ESMO Preceptorship on Breast Cancer. Lugano, Switzerland, 6-7 October 2023.
- Invited Speaker. XXXIII AIRO National Congress. Rimini, Italy, 27-29 October 2023.
- Invited Speaker. Educational Program at 2023 San Antonio Breast Cancer Symposium. San Antonio, Texas (USA), 4-9 December 2023.
- Invited Speaker, Chair. 14th European Breast Cancer Conference (EBCC). Milan, Italy, 20-22 March 2024.
- Invited Speaker. ESMO Breast Cancer 2024. Berlin, Germany, 15-17 May 2024.
- Faculty. 24th Workshop on Methods in Clinical Cancer Research (MCCR). Sint Michielsgestel, Netherlands, 15-21 June 2024.
- Invited Speaker. 17th Annual Meeting of the Korean Society of Medical Oncology & 2024 International Conference (KSMO 2024). Seoul, South Korea, 26-27 September 2024.
- Invited Speaker and Faculty. Breastambul Conference 2024. Istanbul, Turkey, 10-12 October 2024.
- Invited Speaker. San Antonio Breast Cancer Symposium 2024. San Antonio, Texas (USA), 9-12 December 2024.
- Invited Speaker. Breast Cancer at the Limits meeting. London, UK, 10 January, 2025.
- Invited Speaker, Chair & Faculty roles. 2025 ESTRO Annual meeting. Vienna, Austria, 2-5 May, 2025.
- Invited Speaker. ESMO Breast Cancer 2025. Munich, Germany, 15-17 May, 2025.
- Invited Speaker. Educational Session. 2025 ASCO Annual meeting. Chicago, USA, May 30 – June 3, 2025.
- Invited Speaker. 67th American Society for Radiation Oncology (ASTRO) Annual Meeting 2025. San Francisco, CA (USA), 27 Sep – 1 Oct, 2025.
- Invited Speaker. San Antonio Breast Cancer Symposium 2025. San Antonio, Texas (USA), 9-12 December 2025.

Management, organization, and participation in the activities of national and international research groups.

- Co-Chair of the Inter-regional Section Tosco-Umbra of the Italian Association of Radiotherapy Oncology (GTUOR). Biennium 2013-2015.
- Co-Chair of the Breast Cancer Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Biennium 2014-2016.
- Radiation Oncology Group (ROG) and the Breast Cancer Group (BCG) of the European Organization for Cancer Research and Treatment (EORTC). 2014-today.
- Co-Chair of the Breast Working party (BWP) of the ROG of the EORTC. 2013-2018.
- Selected for the program promoted by the European Organization for Cancer Research and Treatment (EORTC): Early Career Investigator (ECI) EORTC Program. 2017-2019.
- European Organization for Research and Treatment of Cancer (EORTC) - Radiation Oncology Group (ROG) -Disease Oriented Groups Junior Representative (jRDR) for Breast Cancer. March 2018-2020.
- Founding Partner and Chair of the National / International Multi-Center Study Group "Clinical Oncology Breast Cancer Group - Group of Clinical Oncology of Breast Cancer" (COBCG). March 2018-today.
- Member the Italian College of Senologists. 2016-2020.
- Member of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). 2006-today.
- Member of the Italian Association of Radiobiology (AIRB).
- Member of European Society for Radiation Oncology (ESTRO) since 2012

- Member of the European Organization for Research and Treatment of Cancer (EORTC) since 2014.
- Writing Committee of Breast Cancer AIRO Italian Guideline. 2017-2018.
- Reviewer Committee of Breast Cancer AIRO Italian Guideline. 2019-2020.
- Reviewer Committee of Breast Cancer Italian Guideline of the Medical Oncology Italian Association (AIOM). 2018-2020.
- Executive Committee of the Biannual Meeting "Attualità in Senologia". Florence. 2019 and 2021.
- Scientific Committee of SenoNetwork. 2020-2022.
- Scientific Committee of the National Meeting AIRO. 2016-2022.
- Chair of the Breast Cancer Group of AIRO. 2020-2022.
- Board Member of the Radiation Oncology Scientific Council (ROSC) EORTC. 2020-present.
- Member of the ESTRO SAG for Clinical Radiotherapy SAG. ESTRO Meeting 2020 (virtual), ESTRO Meeting 2021 (Madrid), and ESTRO Meeting 2022 (Copenhagen).
- Board member of the ESTRO-ACROP guidelines breast cancer focus group. 2022-present.
- Scientific Committee of Tuscany Region Senologic Network on axillary management. Comitato Scientifico Regionale sul Trattamento dell'Ascella. Rete Senologica Toscana. 2021-2022.
- Faculty member of the College of the European School of Oncology (ESO). 2022-present.
- Task force member of Accelerated Partial Breast Irradiation (APBI) Replacement: An ASTRO Evidence-Based Clinical Practice Guideline. March, 2022.
- Faculty member of 13th European Breast Cancer Conference (EBCC). Barcelona, Spain, 16-18 November 2022.
- Faculty member of 18th St. Gallen International Breast Cancer Conference (SGBCC). Vienna, Austria, 15-18 March 2023.
- Faculty member of 13th European Breast Cancer Conference (EBCC). Milan, Italy, March 2024.
- ESTRO clinical Board Member. 2023 – 2026.
- ESTRO Educational Committee (EDC) Board Member. 2023 – present.
- ESTRO-Industry task force Chair. 2024 – present
- ESTRO Clinical Radiotherapy Scientific Advisory Group (SAG) Chair. ESTRO Meeting 2025 (Vienna, Austria).
- Organising Committee of 15th EBCC. Barcelona, Spain, March, 2026.
- ESTRO Clinical Radiotherapy Scientific Advisory Group (SAG) member. ESTRO Meeting 2026 (Stockholm, Sweden).

Responsibility and coordination of scientific works and research

- Co-Principal Investigator. APBI-IMRT-Florence (NCT02104895) phase III trial. Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation. Institution: University of Florence, Italy.
- Sub-Investigator. PERTAIN Trial (Hoffmann-La Roche) A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Hormone Receptor-Positive, HER2-positive Metastatic Breast Cancer patients. NCT01491737.
- Sub-Investigator. SAFE HER trial (Hoffmann-La Roche). A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients with Early HER2-Positive Breast Cancer (SafeHer). NCT01566721.
- Sub-Investigator. BELLE3 trial (Novartis). Randomized, double-blind, placebo-controlled, Phase III trial with BKM120 in combination with fulvestrant in postmenopausal patients with HER2-negative hormone receptor positive, locally advanced or metastatic carcinoma treated with aromatase inhibitors and presented progression during or after therapy with a regimen containing an mTOR inhibitor.
- Sub-Investigator. SAFE phase III trial (NCT02236806). Role of ACE Inhibitors and Beta Blockers as Cardiotoxicity Prevention in Breast Cancer Patients Treated With (Neo) Adjuvant Anthracyclines and / or Trastuzumab: a Four Arm, Placebo Control, Randomized Trial. Institution: University of Florence, Italy.
- Sub-Investigator. GIM13 AMBRA (Oncotech Consortium). Longitudinal cohort study on the therapeutic choices of HER2-negative metastatic breast cancer in Italian clinical practice.

- Sub-Investigator. GIM10 CONSENT (IRCCS AOU San Martino-IST). Phase III clinical study comparing the concomitant and sequential administration of CT and AI as adjuvant treatment of postmenopausal patients with hormone-sensitive breast cancer.
- Sub-Investigator. SANDPIPER Trial (Hoffmann-La Roche). SANDPIPER Study: A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy. NCT02340221.
- Sub-Investigator. BONADIUV phase II trial (NCT02616744). A Single - blind, Randomized, Placebo - controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial. Institution: University of Florence, Italy.
- Sub-Investigator. GIM16 FEVEX (Consorzio Oncotech). Fulvestrant followed by everolimus plus exemestane vs exemestane and everolimus followed by fulvestrant in postmenopausal women with hormone receptor positive (HR +) ad human epidermal growth factor receptor type 2 negative (HER2-) locally advanced (LABC) or metastatic breast cancer (MBC) previously treated with non steroidal aromatase inhibitors (NSAI): a multicentre, phase III trial.
- Sub-Investigator. SINODAR ONE trial (Humanitas Research Foundation - Rozzano, Milan). T1-T2 mammary carcinoma: comparison of excision and preservation of axillary lymph nodes in the presence of metastases to the sentinel lymph node.
- Sub-Investigator. PAINTER trial (Medical Oncology of the Fatebenefratelli Hospital). PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment. NCT02864030.
- Co-Investigator. LUCY Study: Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1 / 2 Mutations. Eudract Code: 2017-001054-34.
- Co-Investigator. Patients With Her2-Positive Unresectable Locally Advanced Or Metastatic Breast Cancer (F. Hoffmann-La Roche Ltd). Protocol Number MO39146.
- Co-Investigator. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Atezolizumab In Combination With Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer "(F. Hoffmann -La Roche Ltd). Protocol Number MO39193. Eudract Number 2016-005119-42.
- Co-Investigator. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of atezolizumab (Anti-PD-L1 antibody) In Combination With Paclitaxel compared With Placebo With Paclitaxel For Patients With Previously Untreated Inoperable Locally Advanced Or Metastatic Triple Negative Breast Cancer (F. Hoffmann-La Roche Ltd). Protocol Number MO39196 Eudract Number 2016-004024-29.
- Co-Investigator. Palbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial Of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone For Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer (Pallas). Alliance Foundation Trials, Llc. Clinicaltrials.Gov Identifier: Nct02513394.
- Co-Investigator. Non-Interventional Study To Characterize The Real World Treatment Patterns And Outcomes Of Women With ER+, HER2- Advanced Or Metastatic Breast Cancer In Italy (Pfizer). Protocol Number A5481031.
- Co-Investigator. Compleement-1: "An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre / postmenopausal women with hormone receptor-positive (HR +) HER2- negative (HER2) advanced breast cancer (BC) with no prior hormone therapy for advanced disease". Eudract Code: 2016-003467-19.
- Principal Investigator. Phase III trial (EUROPA trial). ExclUusive endocRine therapy Or Partial breast irradiation for women aged ≥ 70 years with luminal A-like early stage breast cancer (EUROPA): a randomized phase 3 non-inferiority trial. ClinicalTrial.gov Identifier NCT04134598. Institution: University of Florence.

Scientific responsibility for national and international projects

- Professional Research Assign at the Department of Clinical Physiopathology of the University of Florence, Italy. Topic: "Risk-assessment in Radiotherapy". European

- project no. LSHC-CT-2004-503564 - VI Program MAESTRO (Methods and Advanced Equipment for Simulation and Treatment in Radio Oncology). 10/1/2005 - 01/03/2006.
- Research fellowship Topic "Evaluation of genetic predisposition to induced radio toxicity" (DAI Oncology, SODC Radiotherapy) of the Department of Clinical Pathophysiology of the University of Florence, Italy. (2009 Regional Health Research Grant). 01/07/2010 - 30/07/2011.
- Co-Investigator/Clinical Partner. Tuscan Health Ecosystem (THE) 2022–2025. Funded by Italy's National Recovery and Resilience Plan (NRRP / PNRR). Next Generation EU, Mission 4, Component 2, Investment 1.5. Spoke 2, Personalised Medicine and Innovative Technologies.
- Co-Investigator/Clinical Partner. IMpLeMenting geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAnCer patieNTs (IMPORTANT). Project ID: 101104589. Programme: Horizon Europe – Cancer Mission. Call: HORIZON-MISS-2022-CANCER-01-03.

Participation in editorial committees of Journals and Editorial series

- Cancer and Clinical Oncology (ISSN: 1927-4858, Print; ISSN: 1927-4866, Online)
- Case Reports in Pathology (ISSN: 2090-6781)
- Translational Cancer Research (Translator Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803)
- Subject Editor (Radiation Therapy) Critical Review in Oncology/Hematology (ISSN 1040-8428), 2022 – 2024.
- Editorial Board, Radiotherapy and Oncology (ISSN 0167-8140). 2025 – present.
- Editorial Board, European Journal of Surgical Oncology (EJSO). 2025 – present.

Reviewer for Scientific Journals

- New England Journal of Medicine (NEJM) (ISSN: 0028-4793 / 1533-4406)
- Journal of Clinical Oncology (ISSN: 0732-183X / 1527-7755)
- JAMA Oncology (ISSN: 2374-2437 / 2374-2445)
- The Lancet Oncology (ISSN: 1470-2045)
- Critical Reviews in Oncology/Hematology (ISSN: 1040-8428)
- Radiotherapy and Oncology (ISSN: 0167-8140)
- Future Oncology (ISSN: 1479-6694)
- The Breast (ISSN: 0960-9776)
- Urologic Oncology (ISSN: 1078-1439)
- Clinical Breast Cancer (ISSN: 1526-8209)
- Tumor Biology (ISSN: 1010-4283)
- Medical Radiology (ISSN: 1826-6983)
- Onkologie (ISSN: 1423-0240)
- BMC Cancer (ISSN: 1471-2407)
- Case Reports in Pathology (ISSN: 2090-6781)
- Cancer and Clinical Oncology (ISSN: 1927-4858 / 1927-4866)

Assignments in University teaching courses and research institutes

- Fellowship. Oncology Radiotherapy Unit - Radiation Oncology Unit, Royal Marsden Hospital, London (UK). Supervisor: Prof. Michael Brada from 01.10.2008 to 31.03.2009. Clinical activity at the "Royal Marsden Hospital" (RMH), London (UK) and research activity at The Institute of Cancer Research (ICR), London, Sutton (UK). Consulting at the Chelsea and Sutton institute of the RMH specialized in lung and brain cancer (Prof. Michael Brada). Outpatient clinical activity at the Sutton site of the specialized RMH in hematological malignancies (Prof. Alan Horwich). Discussion and participation in Multi-Disciplinary Team (MDT) of lung cancer (Sutton's RMH site) and cerebral cancer (St. George Hospital, Wimbledon, London).
- Frontal teaching and student tutor in Master's Degree course, Medical School and Three-year Degree Course in Medical Radiology Techniques.
- Frontal teaching and mentoring in specialized training Specialization school in Radiation Oncology AOUC Florence.
- Thesis co-supervisor (Supervisor Prof. Lorenzo Livi) Medical School, University of Florence, Italy.
- Local Speaker of the Advanced Course on Multidisciplinary Breast Cancer Treatment of the European Society of Radiotherapy Oncology (ESTRO), ESTRO Teaching Course

on the Multidisciplinary Management of Breast Cancer 2015, ESTRO School of Radiation Oncology.

- Teacher of the ESTRO Teaching Course on Accelerated partial Breast Irradiation. 2020-present.
- Teacher Faculty. II Degree Master on "Oncologic Drugs and Radiotherapy". University of Brescia, Brescia, Italy. 2023-present.

University of Florence academic teaching courses:

- **Medical Radiology, Imaging Techniques, and Radiotherapy (2018 – 2020)**
DIAGNOSTIC IMAGING TECHNIQUES II [B019930, B024640, B029359]
GENERAL RADIOLOGY DIAGNOSTIC TECHNIQUES - SENIOLOGY AND INTERVENTIONAL RADIOLOGY [B029341]
- **Healthcare Assistance (2020 – 2021)**
PREVENTIVE SCIENCES [B020074, B030150]
- **Obstetrics (2021 – present)**
HEALTH AND SAFETY PROMOTION [B030999]
- **Nursing (2018 – present)**
DIAGNOSTIC AND THERAPEUTIC PROCESSES [B030242]
- **Medicine and Surgery (2018 – present)**
DIAGNOSTIC IMAGING (INTEGRATED COURSE) [0090435]

Clinical activity

Radiation Oncology Unit - AOU Careggi, Florence (Head: Prof. Lorenzo Livi).

Position: Consultant Radiation Oncologist; Head of the Breast Unit and Chair of the Breast Cancer Multidisciplinary Team (MDT).

Main responsibilities and areas of activity:

- Comprehensive involvement in clinical, diagnostic, therapeutic, and follow-up care for oncology patients, with active participation in multidisciplinary team meetings (MDTs); integration of radiotherapy with chemotherapy, targeted and molecular therapies, supportive and palliative care.
- Leadership of the Breast Unit at AOUC Florence University Hospital and coordination of the Breast Cancer MDT.
- Day-hospital activities including the administration and supervision of chemotherapy and targeted therapies across primary, adjuvant, and metastatic settings; management of treatment reassessments and supportive care; participation in national and international clinical trials (both academic and industry-sponsored).
- Radiotherapy planning responsibilities including early treatment consultations, toxicity assessments, and technical planning of treatments; experience with linear accelerators, tomotherapy, GammaKnife, and CyberKnife platforms.
- Skilled in treatment planning systems for standard, conformational, stereotactic, IMRT, and VMAT treatments (XiO, Odyssey, Pinnacle, Monaco).
- Proficient in record & verify systems, PACS for radiological imaging, and patient positioning and immobilisation systems.

All the information provided in this curriculum vitae is accurate and truthful. I authorize the processing of my personal data in accordance with EU Regulation 2016/679 on the protection of personal data (GDPR). Any unauthorized use or disclosure of this information is prohibited. I declare that I am aware that the personal data provided will be treated with the utmost confidentiality and used exclusively for the purposes of the current selection process.

Florence, Italy
13/07/2025

Prof. Icro Meattini

Firenze, 29 luglio 2025

Oggetto: Candidatura per la posizione di Consigliere – Gruppo Mammella AIRO

Gentile Comitato AIRO,

con la presente desidero sottoporre la mia candidatura per la posizione di Consigliere del Gruppo di Studio Mammella di AIRO.

Attualmente ricopro il ruolo di Direttore della Breast Unit e Coordinatore del Gruppo Multidisciplinare di Senologia presso l'Azienda Ospedaliero-Universitaria Careggi di Firenze. Sono Professore Associato di Oncologia e Radioterapia presso l'Università di Firenze e Dirigente Oncologo Clinico presso l'Unità di Radioterapia della stessa Azienda. Da oltre quindici anni mi occupo in maniera continuativa di ricerca clinica, attività accademica e assistenziale nell'ambito del carcinoma mammario, con particolare interesse verso i trattamenti conservativi, l'integrazione radio-farmacologica, la senescenza oncologica e l'ottimizzazione della qualità di vita delle pazienti.

Sono autore di oltre 300 pubblicazioni scientifiche peer-reviewed, molte delle quali dedicate all'oncologia senologica e al ruolo della radioterapia nel percorso terapeutico integrato. Coordino numerosi studi clinici accademici e collaboro attivamente con le principali società scientifiche oncologiche nazionali e internazionali, tra cui AIRO, ESTRO, ESMO ed EORTC. Attualmente sono membro del Consiglio Direttivo di ESTRO e Editor della rivista *Radiotherapy & Oncology* di ESTRO.

Ho contribuito alla stesura di linee guida e consensus internazionali e continuo a promuovere la centralità della radioterapia nella gestione moderna del tumore della mammella.

La mia candidatura nasce dalla profonda convinzione dell'importanza del lavoro collegiale e dell'approccio multidisciplinare nella gestione delle pazienti affette da tumore al seno. Ritengo che AIRO debba continuare a svolgere un ruolo guida nell'ambito senologico, promuovendo ricerca di qualità, formazione per i giovani specialisti e dialogo costruttivo con le altre discipline. Se eletto, mi impegno a mettere a disposizione la mia esperienza nazionale e internazionale, promuovendo progettualità condivise, mentoring, sinergie con altri gruppi cooperativi e una sempre maggiore visibilità scientifica del gruppo mammella.

Ringraziandovi per l'attenzione e restando a disposizione per ogni ulteriore informazione, porgo i miei più cordiali saluti.

Prof. Icro Meattini



Icro Meattini, MD, Associate Professor
Department of Experimental and Clinical Biomedical Sciences "M. Serio" - University of Florence
Head, Breast Unit - Florence University Hospital, Florence, Italy
Consultant, Radiation Oncology Unit, Oncology Department - Florence University Hospital
ESTRO Board Member - ESTRO Breast Focus Group & Guidelines Committee
EORTC Breast Cancer Group Steering Committee - EORTC Radiation Oncology Science Council

Prof. Icro Meattini
Dipartimento di Scienze Biomediche Sperimentali e Cliniche "M. Serio" - Università di Firenze
Direttore, Breast Unit - Azienda Ospedaliero Universitaria Careggi (AOUC), Firenze
Radioterapia Oncologica, Dipartimento di Oncologia - AOUC, Firenze
E-mail: icro.meattini@unifi.it



**Azienda
Ospedaliero
Universitaria
Careggi**